A Placebo-controlled Trial of Roflumilast (Daliresp) on Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2015
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Pharmacodynamics
- 07 Jul 2015 Results published in the American Journal of Respiratory and Critical Care Medicine.
- 01 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned number of patients changed from 40 to 30 as reported by ClinicalTrials.gov.